首页> 美国政府科技报告 >Protein IsG15 Modification in the Development and the Treatment of Chronic Myeloid Leukemia
【24h】

Protein IsG15 Modification in the Development and the Treatment of Chronic Myeloid Leukemia

机译:蛋白质IsG15修饰在慢性粒细胞白血病的发展和治疗中的应用

获取原文

摘要

Interferons are useful drugs in treating chronic myeloid leukemia (CML). One of the cellular responses of interferon treatment is the activation of protein modification by ISO 15. We have cloned a novel gene encoding a protease UBP43 that specifically removes 15015 from 15015 modified proteins. Furthermore, we have generated UBP43 knockout mice. UBP43 deficient hematopoietic cells have much higher levels of ISO 15 modified proteins upon interferon stimulation and are hypersensitive to interferon treatment. This grant is to demonstrate that protein ISG15 modification is crucial for interferon function in CML treatment and to analyze the effect of UBP43 on CML development. In the past funding period, we have established BCR/ABL positive leukemia cell lines that have higher than normal or lower than normal level of ISG15 conjugation and initiated the characterization of these cell lines. Furthermore, we have generated additional important data to support that UBP43 knockout mice are resistant to BCR/ABL induced CML development and that interferon plays a critical role in this process. We will continue to perform experiments as proposed in the application to establish the role of 15015 modification and UBP43 in interferon signaling and CML development.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号